# Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

> **NCT06084845** · PHASE2 · WITHDRAWN · sponsor: **ECOG-ACRIN Cancer Research Group**

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Hypopharyngeal Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Hypopharyngeal Carcinoma AJCC v8
- Stage IV Laryngeal Cancer AJCC v8
- Stage IV Lip and Oral Cavity Cancer AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Chest Radiography
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **RADIATION:** Image Guided Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Xevinapant

## Key facts

- **NCT ID:** NCT06084845
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-12
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** A phase III trial of the investigational agent failed to pass futility boundaries at interim analysis
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084845, "Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06084845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*